SELLAS Life Sciences Closes $20M Public Offering
Ticker: SLS · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1390478
| Field | Detail |
|---|---|
| Company | Sellas Life Sciences Group, Inc. (SLS) |
| Form Type | 8-K |
| Filed Date | Mar 11, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | bullish |
Sentiment: bullish
Topics: public-offering, financing, biotech
TL;DR
SELLAS closed its $20M stock offering at $6.50/share, raising crucial capital for pipeline development.
AI Summary
On March 11, 2024, SELLAS Life Sciences Group, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully raised approximately $20.0 million in gross proceeds before deducting underwriting discounts and commissions and other offering expenses. This offering involved the sale of 3,076,923 shares of common stock at a price of $6.50 per share.
Why It Matters
The successful completion of this public offering provides SELLAS Life Sciences Group with additional capital, which can be used to fund its ongoing clinical trials and general corporate purposes, potentially advancing its drug development pipeline.
Risk Assessment
Risk Level: medium — While the capital raise is positive, the company operates in the volatile biotech sector with inherent risks associated with drug development and market acceptance.
Key Numbers
- $20.0M — Gross Proceeds (Raised from the public offering to fund operations and development.)
- 3,076,923 — Shares Sold (Represents the volume of common stock issued in the offering.)
- $6.50 — Price Per Share (The price at which each share was sold to investors.)
Key Players & Entities
- SELLAS Life Sciences Group, Inc. (company) — Registrant
- March 11, 2024 (date) — Closing date of the offering
- $20.0 million (dollar_amount) — Gross proceeds from the offering
- 3,076,923 (number) — Number of shares sold
- $6.50 (dollar_amount) — Price per share
FAQ
What was the total amount of gross proceeds raised by SELLAS Life Sciences Group in this offering?
SELLAS Life Sciences Group raised approximately $20.0 million in gross proceeds.
On what date did SELLAS Life Sciences Group announce the closing of its public offering?
The closing of the public offering was announced on March 11, 2024.
How many shares of common stock were sold in the offering?
A total of 3,076,923 shares of common stock were sold.
At what price per share were the shares sold?
The shares were sold at a price of $6.50 per share.
What is the primary use of the funds raised from this offering?
The funds are intended to be used for ongoing clinical trials and general corporate purposes.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-03-11 16:05:35
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SLS The Nasdaq St
- $1.00 — price of the Company's common stock of $1.00 per share for the last 10 consecutive b
Filing Documents
- tm248504d1_8k.htm (8-K) — 25KB
- 0001104659-24-032964.txt ( ) — 194KB
- sls-20240311.xsd (EX-101.SCH) — 3KB
- sls-20240311_lab.xml (EX-101.LAB) — 33KB
- sls-20240311_pre.xml (EX-101.PRE) — 22KB
- tm248504d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On March 11, 2024, SELLAS Life Sciences Group, Inc. (the "Company") received a letter from The Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement") by maintaining a minimum closing bid price of the Company's common stock of $1.00 per share for the last 10 consecutive business days, from February 26, 2024 to March 8, 2024, and that this matter is now closed. As previously disclosed, on February 14, 2024, the Company received a letter from Nasdaq indicating that the Company was not in compliance with the Minimum Bid Price Requirement because, for a period of 30 consecutive business days, the closing bid price had not maintained a minimum of $1.00 per share. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a grace period of 180 calendar days, or until August 12, 2024, to regain compliance with the Minimum Bid Price Requirement. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SELLAS Life Sciences Group, Inc. Date: March 11, 2024 By: /s/ John Burns Name: John Burns Title: Senior Vice President, Chief Financial Officer 3